The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.

Here's the latest list of major oversold players in this sector, having an RSI near or below 30.

Rocket Pharmaceuticals Inc (NASDAQ:RCKT)

• On Dec. 11, Rocket Pharmaceuticals announced a $165 million upsized public offering of 13.2 million shares at $12.50 per share. The company's stock fell around 10% over the past month and has a 52-week low of $11.15.
• RSI Value: 26.8                          
• RCKT Price Action: Shares of Rocket Pharmaceuticals fell 1.3% to close at $12.56 on Friday.
• Benzinga Pro's real-time newsfeed alerted to latest RCKT news.

Inovio Pharmaceuticals Inc (NASDAQ:INO)     

• On Dec. 13, Inovio Pharmaceuticals announced a public offering of 10 million shares for gross proceeds of $30 million.. The company's stock fell around 53% over the past month and has a 52-week low of $1.74.
• RSI Value: 18.5
• INO Price Action: Shares of Inovio Pharmaceuticals gained 7.7% to close at $1.96 on Friday.
• Benzinga Pro’s charting tool helped identify the trend in INO stock.

Outlook Therapeutics Inc (NASDAQ:OTLK)

• On Dec. 27, Outlook Therapeutics announced a year-over-year increase in FY24 EPS results. “Over the course of the past year, our team has continued to execute and progress the development of ONS-5010/LYTENAVA™ in Europe and the United States. Following the receipt of our first positive reimbursement decision worldwide for LYTENAVA™ from NICE in the United Kingdom, our team continues to make preparations for commercial launch in the UK and Germany, which is expected in the first half of calendar 2025,” commented Lawrence Kenyon, Chief Financial Officer and Interim Chief Executive Officer of Outlook Therapeutics. The company's stock fell around 72% over the past six months and has a 52-week low of $0.87.
• RSI Value: 26.9
• OTLK Price Action: Shares of Outlook Therapeutics gained 8.8% to close at $2.24 on Friday.
• Benzinga Pro’s signals feature notified of a potential breakout in OTLK shares.

Read This Next:

• Delta Air Lines Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call